501 related articles for article (PubMed ID: 23666687)
1. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
2. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
Ballestrero A; Cirmena G; Dominietto A; Garuti A; Rocco I; Cea M; Moran E; Nencioni A; Miglino M; Raiola AM; Bacigalupo A; Patrone F
Int J Lab Hematol; 2010 Aug; 32(4):387-91. PubMed ID: 19968720
[TBL] [Abstract][Full Text] [Related]
4. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
Sadia H; Siddiqui RT; Nasim A
Cancer Genet Cytogenet; 2010 Aug; 201(1):57-61. PubMed ID: 20633771
[TBL] [Abstract][Full Text] [Related]
5. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.
Jönsson S; Olsson B; Jacobsson S; Palmqvist L; Ricksten A; Ekeland-Sjöberg K; Wadenvik H
Scand J Clin Lab Invest; 2011 Feb; 71(1):7-11. PubMed ID: 20863169
[TBL] [Abstract][Full Text] [Related]
7. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Horváth A; Baghiu MD; Pap Z; Bănescu C; Mărginean CO; Pávai Z
Rom J Morphol Embryol; 2011; 52(3):907-13. PubMed ID: 21892537
[TBL] [Abstract][Full Text] [Related]
9. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
11. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
12. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
13. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
15. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
16. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
18. [Genetic diagnosis of chronic myeloid leukemia].
Kato C; Naoe T
Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Ribeiro BF; Vergílio BR; Miranda EC; Almeida MH; Delamain MT; da Silveira RA; de Souza CA; Albuquerque DM; Santos AD; Duarte VO; Oliveira-Duarte GB; Lorand-Metze I; Pagnano KB
Acta Haematol; 2015; 134(4):248-54. PubMed ID: 26159458
[TBL] [Abstract][Full Text] [Related]
20. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
